|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: INSL6 |
Gene summary for INSL6 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | INSL6 | Gene ID | 11172 |
| Gene name | insulin like 6 | |
| Gene Alias | RIF1 | |
| Cytomap | 9p24.1 | |
| Gene Type | protein-coding | GO ID | GO:0007154 | UniProtAcc | Q9Y581 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 11172 | INSL6 | S014 | Human | Liver | HCC | 3.04e-33 | 8.42e-01 | 0.2254 |
| 11172 | INSL6 | S015 | Human | Liver | HCC | 5.98e-31 | 1.05e+00 | 0.2375 |
| 11172 | INSL6 | S016 | Human | Liver | HCC | 1.35e-41 | 9.76e-01 | 0.2243 |
| Page: 1 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| Page: 1 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| INSL6 | SNV | Missense_Mutation | c.166N>A | p.Glu56Lys | p.E56K | Q9Y581 | protein_coding | tolerated(0.12) | benign(0.01) | TCGA-AN-A046-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
| INSL6 | SNV | Missense_Mutation | rs780234860 | c.388N>A | p.Glu130Lys | p.E130K | Q9Y581 | protein_coding | tolerated(0.34) | possibly_damaging(0.475) | TCGA-BH-A0BC-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | doxorubicin | SD |
| INSL6 | SNV | Missense_Mutation | c.429G>T | p.Glu143Asp | p.E143D | Q9Y581 | protein_coding | tolerated(0.16) | benign(0.287) | TCGA-AA-A00N-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | PD | |
| INSL6 | SNV | Missense_Mutation | rs373690238 | c.7C>T | p.Arg3Trp | p.R3W | Q9Y581 | protein_coding | deleterious(0) | benign(0.063) | TCGA-AA-A024-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD |
| INSL6 | SNV | Missense_Mutation | c.256N>A | p.Ala86Thr | p.A86T | Q9Y581 | protein_coding | tolerated(1) | benign(0) | TCGA-CM-6171-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
| INSL6 | SNV | Missense_Mutation | c.206N>T | p.Ser69Leu | p.S69L | Q9Y581 | protein_coding | tolerated(0.32) | benign(0.005) | TCGA-F4-6460-01 | Colorectum | colon adenocarcinoma | Female | <65 | III/IV | Chemotherapy | capecitabine | PD | |
| INSL6 | SNV | Missense_Mutation | c.512G>A | p.Arg171His | p.R171H | Q9Y581 | protein_coding | tolerated(0.05) | probably_damaging(0.999) | TCGA-F4-6855-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
| INSL6 | SNV | Missense_Mutation | c.53N>A | p.Arg18Gln | p.R18Q | Q9Y581 | protein_coding | tolerated(0.34) | possibly_damaging(0.511) | TCGA-G4-6317-01 | Colorectum | colon adenocarcinoma | Female | <65 | III/IV | Chemotherapy | fluorouracil | PD | |
| INSL6 | insertion | Frame_Shift_Ins | novel | c.613dupA | p.Arg205LysfsTer7 | p.R205Kfs*7 | Q9Y581 | protein_coding | TCGA-AA-A010-01 | Colorectum | colon adenocarcinoma | Female | <65 | I/II | Chemotherapy | folinic | CR | ||
| INSL6 | insertion | Frame_Shift_Ins | novel | c.376_377insTACATCCT | p.Gly126ValfsTer36 | p.G126Vfs*36 | Q9Y581 | protein_coding | TCGA-AM-5820-01 | Colorectum | colon adenocarcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| Page: 1 2 3 4 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |